In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Caught In WHI Wake

Executive Summary

Disturbing news from a major hormone study, bad regulatory luck, and a botched attempt to reassure German gynecologists have hurt Schering's HRT business. Yet the company hopes to use its risk-lowering franchise strategy to distinguish its HRT products from competitors'.

You may also be interested in...



Schering: Addressing the Specialist Challenge

As a large yet specialist firm, Schering must compete in multiple areas. That means developing and marketing differentiated products across a number of fronts--and dealing with the lower-than-average margins that typically come with mixed portfolios. How well the German group overcomes these challenges should be of growing interest to Big Pharma, given the risks of relying on blockbusters.

Galen's Generic Gamble

Galen's $359 million acquisition of Pfizer's women's health portfolio fits in well with the group's strategy to date. But the structure of the deal also highlights Galen's increasing exposure to generic competition.

Akzo Pharma's Fall and Rise

The recent meltdown at Akzo Nobel's Pharma unit was caused by a perfect storm of genericization, macroeconomic gloom, pipeline delays and product underperformance. But Akzo Pharma hopes that by beefing up R&D and cutting costs through restructuring, it can return to growth in 2005.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel